ANCA Testing Demystified: When to Order, How to Interpret, and When to Leave It Alone

 

ANCA Testing Demystified: When to Order, How to Interpret, and When to Leave It Alone

Vasculitis serologies are powerful—but ordering them for the wrong reasons creates more problems than it solves.

ANCA testing is one of the most misused lab panels in primary care. It gets ordered for vague joint pain, nonspecific rashes, or an elevated ESR—and then a low-positive p-ANCA comes back, everyone panics, and the patient gets a workup they never needed. Meanwhile, the patient with bloody nasal crusting and rising creatinine who actually has vasculitis sometimes gets missed because nobody thought to test.

Let's fix that.

What Is ANCA, and What Are We Actually Testing?

ANCA stands for Anti-Neutrophil Cytoplasmic Antibodies. These are autoantibodies directed against proteins inside neutrophils, and they're the serologic hallmark of a group of rare, serious, small-vessel vasculitides collectively called ANCA-associated vasculitis (AAV).

AAV includes three diseases:

• Granulomatosis with polyangiitis (GPA) — formerly Wegener's. Affects the upper and lower respiratory tract and kidneys. Often presents with chronic sinusitis, nasal crusting/bleeding, pulmonary nodules, and glomerulonephritis.
• Microscopic polyangiitis (MPA) — predominantly affects kidneys and lungs. Often presents as rapidly progressive glomerulonephritis and/or alveolar hemorrhage.
• Eosinophilic granulomatosis with polyangiitis (EGPA) — formerly Churg-Strauss. Late-onset asthma, eosinophilia, and multisystem vasculitis. ANCA-positive in only about 30–40% of cases.

The Two Testing Methods: IIF vs. Antigen-Specific Assays

There are two layers to ANCA testing, and understanding both is key to interpreting results correctly:

Indirect Immunofluorescence (IIF) — The Pattern

The original method. Patient serum is applied to ethanol-fixed neutrophils, and the fluorescence pattern is read under a microscope:

• c-ANCA (cytoplasmic pattern) — diffuse granular staining of the cytoplasm. In the context of vasculitis, this is almost always caused by antibodies against proteinase 3 (PR3).
• p-ANCA (perinuclear pattern) — staining concentrated around the nucleus. In vasculitis, this is usually caused by antibodies against myeloperoxidase (MPO).
• Atypical ANCA — positive IIF but negative for both PR3 and MPO on specific assays. This pattern is common in IBD, autoimmune liver disease, and other non-vasculitic conditions. It is not specific for AAV.

Antigen-Specific Assays (ELISA/CLIA) — The Target

These directly measure antibodies against the two key proteins:

• PR3-ANCA (anti-proteinase 3) — the antibody behind most c-ANCA patterns
• MPO-ANCA (anti-myeloperoxidase) — the antibody behind most p-ANCA patterns

Critical Update

Current international guidelines now recommend that antigen-specific testing (PR3 and MPO) can be used as the primary screening method, without requiring IIF first. Many reference labs now default to this approach. The key point: a positive PR3-ANCA or MPO-ANCA in the right clinical context is sufficient to support an AAV diagnosis. IIF alone, particularly an isolated p-ANCA without a positive MPO, is often clinically meaningless for vasculitis.

PR3-ANCA vs. MPO-ANCA: They're Not the Same Disease

Increasingly, experts advocate classifying patients by ANCA serotype rather than just the traditional disease names. The antibody type predicts behavior better than the clinical label alone:

PR3-ANCA (c-ANCA)

• Strongly associated with GPA
• ENT involvement: bloody nasal crusting, sinusitis, saddle-nose deformity, subglottic stenosis
• Pulmonary: nodules, cavitary lesions, alveolar hemorrhage
• Renal: glomerulonephritis
• Higher relapse rate
• More organs typically involved
• More common in Northern European/White populations
• ~75% of GPA patients are PR3-positive

MPO-ANCA (p-ANCA)

• Strongly associated with MPA
• Renal-dominant: often presents as rapidly progressive GN
• Pulmonary: interstitial lung disease, fibrosis, alveolar hemorrhage
• Less ENT involvement
• Lower relapse rate (but relapses still occur)
• More common in Asian and Southern European populations
• ~70% of MPA patients are MPO-positive
• Also seen in ~40% of EGPA

The Pitfalls: Where Primary Care Gets Into Trouble

1. Ordering ANCA for Nonspecific Symptoms

This is pitfall number one, and it's rampant. ANCA gets ordered for fatigue, myalgias, elevated ESR, nonspecific rash, or vague joint pain—and then a low-positive p-ANCA comes back. This almost never means vasculitis.

Remember: p-ANCA (by IIF) without a positive MPO-ANCA is found in a long list of non-vasculitic conditions:

• Inflammatory bowel disease (Crohn's and UC)
• Autoimmune hepatitis and primary sclerosing cholangitis
• Rheumatoid arthritis
• SLE (15–20% of lupus patients can be ANCA-positive)
• Infections
• Various medications

Rule of Thumb

If you don't have a specific clinical reason to suspect small-vessel vasculitis, don't order ANCA. A low pretest probability + a low-positive ANCA = a false positive that generates anxiety, unnecessary referrals, and potentially harmful biopsies. ANCA testing should be driven by clinical suspicion, not used as a screening tool for nonspecific inflammation.

2. Ignoring the 5–10% Who Are ANCA-Negative

Here's the flip side: approximately 5–10% of patients with biopsy-proven GPA or MPA are ANCA-negative. Up to 70% of EGPA patients are seronegative. A negative ANCA does not rule out vasculitis if the clinical picture is compelling. If you have a patient with rapidly progressive glomerulonephritis, pulmonary-renal syndrome, or destructive upper airway disease, they need a rheumatology or nephrology referral regardless of the ANCA result.

3. Confusing "Atypical p-ANCA" with AAV

An atypical ANCA pattern—positive on IIF but negative for both PR3 and MPO—is not associated with ANCA-associated vasculitis. It's most commonly seen in IBD and autoimmune liver diseases. Ordering the antigen-specific assays (PR3 and MPO) is what distinguishes a clinically meaningful result from noise.

4. Drug-Induced ANCA Vasculitis

Several medications can trigger ANCA production and even clinical vasculitis:

• Propylthiouracil (PTU) — the most well-known offender; can cause MPO-ANCA-positive vasculitis with glomerulonephritis and alveolar hemorrhage
• Hydralazine — another common culprit, especially with long-term use
• Minocycline
• Levamisole-adulterated cocaine — causes dual PR3 + MPO positivity with skin lesions and arthralgias
• Anti-TNF agents (infliximab, etanercept) — rare but reported

Clinical Pearl

Always take a thorough medication and substance use history before attributing ANCA positivity to primary vasculitis. Drug-induced ANCA vasculitis often resolves after stopping the offending agent, though severe cases may still require immunosuppression for induction.

5. Using ANCA to Monitor Disease Activity (It's Complicated)

This is a nuanced area. Rising PR3-ANCA levels have a moderately useful association with relapse in GPA—but it's not reliable enough to change treatment based on serology alone. For MPO-ANCA, the data is even less clear. Current practice: serial ANCA levels can be one piece of the monitoring puzzle, but treatment decisions should be based on clinical disease activity, not solely on rising titers.

6. ANCA Can Be Positive After COVID-19 Vaccination (Rarely)

Case reports have described new-onset AAV following SARS-CoV-2 vaccination, including rare cases of dual PR3/MPO positivity. This is exceedingly rare relative to the hundreds of millions of doses administered, but it's worth noting if you see a patient develop vasculitis symptoms in temporal association with vaccination.

When Should NPs Order ANCA?

Order ANCA (PR3 and MPO) When You See

• Rapidly progressive glomerulonephritis (rising creatinine + active urine sediment with RBCs/casts)
• Pulmonary-renal syndrome (GN + alveolar hemorrhage/hemoptysis)
• Chronic destructive sinusitis with bloody/crusting nasal discharge not responding to standard treatment
• Pulmonary nodules or cavitary lesions without clear infectious etiology
• Unexplained alveolar hemorrhage (hemoptysis + bilateral infiltrates)
• Palpable purpura or cutaneous vasculitis
• Mononeuritis multiplex (asymmetric peripheral nerve deficits)
• New-onset severe asthma + eosinophilia + multisystem symptoms (think EGPA)
• Scleritis or orbital pseudotumor
• Subglottic stenosis (especially in a younger patient)

Do NOT Order ANCA For

• Nonspecific fatigue or myalgias
• Isolated elevated ESR or CRP without organ-specific findings
• Generalized arthralgias without evidence of vasculitis
• Routine ANA workup add-on (ANCA and ANA are completely different pathways)
• Nonspecific rashes or urticaria
• "Just to be thorough" — this is how false positives are born

Quick-Reference Table

Pattern/Antibody	Primary Association	Key Pitfall
c-ANCA / PR3-ANCA	GPA (Wegener's); ~90% concordance between c-ANCA and PR3	Higher relapse rate; rising titers may precede flare but aren't reliable enough alone to change therapy
p-ANCA / MPO-ANCA	MPA, EGPA, drug-induced vasculitis	p-ANCA pattern on IIF WITHOUT positive MPO is usually IBD, autoimmune liver disease, or other non-vasculitic cause
Atypical ANCA	IBD (especially UC), autoimmune hepatitis, PSC	NOT associated with AAV. Don't refer for vasculitis workup based on this alone.
ANCA-negative AAV	5–10% of GPA/MPA; up to 70% of EGPA	Negative ANCA does NOT exclude vasculitis. Biopsy may still be needed if clinical suspicion is high.
Drug-induced ANCA	PTU, hydralazine, minocycline, levamisole/cocaine	Usually MPO-ANCA positive; often resolves after stopping the offending drug. Always take a med/substance history.

The Diagnostic Workflow for Primary Care

1. Clinical suspicion first. Don't order ANCA without organ-specific signs pointing toward small-vessel vasculitis.
2. Order PR3-ANCA and MPO-ANCA (antigen-specific assays). Some labs will reflex to IIF if positive; others run all three simultaneously.
3. Get a urinalysis with microscopy at the same time. Active sediment (dysmorphic RBCs, RBC casts, proteinuria) in the setting of positive ANCA is an emergency.
4. Check CRP, ESR, CBC, BMP (creatinine!), and a chest X-ray if pulmonary symptoms are present.
5. Refer urgently. AAV can be life-threatening. If you have a positive PR3 or MPO with compatible clinical findings, this is a same-week (or same-day) referral to rheumatology or nephrology. Do not wait for the specialist appointment to recheck labs.
6. If ANCA is positive but the clinical picture doesn't fit (no organ involvement, no active sediment, no pulmonary findings), don't panic. Consider the pretest probability and alternative explanations (medications, IBD, other autoimmune disease). Refer for evaluation but communicate clearly that the clinical question is "is this a real positive?"

Bottom Line

ANCA testing is powerful but only when it's ordered for the right reasons. The diseases it helps diagnose—GPA, MPA, EGPA—are rare, aggressive, and treatable, but they require a high index of suspicion and a disciplined approach to testing. A positive ANCA in the right clinical context can be lifesaving. A positive ANCA in the wrong context is just noise that generates expensive, anxiety-provoking workups for conditions the patient doesn't have.

Know when to order it. Know what the patterns mean. And know when to leave it alone.

Stay sharp out there.

The Antiphospholipid Antibody Panel: What Every NP Needs to Know (and the Pitfalls That'll Bite You) Unexplained clots, pregnancy losses, and a lab panel that's trickier than it looks.

 

The Antiphospholipid Antibody Panel: What Every NP Needs to Know (and the Pitfalls That'll Bite You)

Unexplained clots, pregnancy losses, and a lab panel that's trickier than it looks.

Antiphospholipid syndrome (APS) is one of those diagnoses that's simultaneously under-recognized and over-tested. In primary care, we see the patients who present with the red flags—unexplained DVT in a 30-year-old, recurrent pregnancy losses, a stroke in someone who "shouldn't" be having one. But the lab panel itself is full of pitfalls that can lead to misdiagnosis in both directions.

Let's walk through this one together.

What Is APS, in Plain English?

APS is an autoimmune disorder where the body produces antibodies against phospholipid-binding proteins. Despite the name "antiphospholipid" (which sounds like it should cause bleeding), these antibodies paradoxically cause clotting—both venous and arterial—plus pregnancy complications. APS can occur alone (primary APS) or in association with another autoimmune disease, most commonly SLE (secondary APS).

The Three Tests You Need to Know

The antiphospholipid antibody panel consists of three categories of tests. All three should be ordered together.

1

Lupus Anticoagulant (LA)
A functional coagulation assay (not an antibody level). Detected using phospholipid-dependent clotting tests, typically dRVVT (diluted Russell's viper venom time) and a sensitive aPTT. Despite the name, it's not specific to lupus, and despite being called an "anticoagulant," it causes clotting in vivo. The name is purely historical. LA is the single strongest predictor of thrombotic events.

2

Anticardiolipin Antibodies (aCL)
Measured as IgG and IgM isotypes by ELISA. Only moderate-to-high titers are clinically meaningful (generally >40 GPL/MPL, or >99th percentile per the lab). Low-positive titers are common in the general population, in infections, and in the elderly—they usually don't indicate APS. IgG isotype carries higher clinical risk than IgM.

3

Anti-β2-Glycoprotein I Antibodies (aβ2GPI)
Also measured as IgG and IgM by ELISA. β2GPI is the actual protein target of most pathogenic antiphospholipid antibodies. Like aCL, only moderate-to-high titers matter. This test adds diagnostic sensitivity—some patients with APS are positive for aβ2GPI but negative for aCL.

The Risk Hierarchy: Single, Double, and Triple Positive

Not all positive aPL profiles carry the same risk. This is critical for counseling patients and deciding management intensity:

aPL Profile	Risk Level	Clinical Implication
Triple positive (LA + aCL + aβ2GPI)	Highest risk	Strongest association with thrombosis and pregnancy morbidity. Often warrants lifelong anticoagulation after a thrombotic event.
Double positive (any two of three)	High risk	Significant clinical risk. Management depends on clinical context.
Single positive (one test only)	Lower risk	Especially if low-titer aCL or aβ2GPI only. May not represent true APS. Always confirm with repeat testing.
Isolated low-titer IgM (aCL or aβ2GPI)	Uncertain	Frequently non-specific. Can be seen with infections, medications, and aging. Rarely clinically significant alone.

The Pitfalls: This Is Where It Gets Messy

1. The 12-Week Confirmatory Rule

This is the single most important rule in APS testing: a positive aPL test must be confirmed with a repeat test at least 12 weeks later. Transient aPL positivity is extremely common—it occurs with infections (especially viral, including COVID-19), medications, and inflammatory states. A single positive test is NOT diagnostic. Per the 2023 ACR/EULAR classification criteria, the positive aPL test must occur within 3 years of the clinical event.

Critical Pitfall

Do NOT diagnose APS or start lifelong anticoagulation based on a single positive aPL panel. Always repeat at ≥12 weeks. Transient positivity after infections (including COVID-19, EBV, and other viral illnesses) is very common and does not equal APS.

2. Lupus Anticoagulant + Anticoagulation = Testing Nightmare

Here's the catch-22: most patients being tested for APS after a clot are already on anticoagulation. But LA testing is based on clotting-time assays, which are directly affected by:

• Heparin/LMWH — can cause false-positive LA results
• Warfarin — prolongs clotting times, making LA interpretation unreliable
• DOACs (direct oral anticoagulants) — particularly problematic; rivaroxaban and apixaban interfere with dRVVT and can cause false-positive LA results

Practical Tip

If LA testing is needed in an anticoagulated patient, discuss timing with your hematologist. Some labs offer DOAC-neutralizing agents (like DOAC-Stop) to mitigate interference, but this isn't universally available. aCL and aβ2GPI are not affected by anticoagulation—these solid-phase immunoassays can be drawn at any time.

3. "Classification Criteria" ≠ "Diagnostic Criteria"

This is a nuance that trips up a lot of clinicians. The 2023 ACR/EULAR APS classification criteria were designed for research standardization, not clinical diagnosis. They are highly specific (99%) but less sensitive (84%). In clinical practice, your judgment matters: a patient with classic livedo racemosa, pregnancy losses, and moderate-titer aCL may have APS even if they don't meet every classification criterion. Conversely, a single low-positive aCL in an elderly patient with a DVT and multiple traditional risk factors probably isn't APS.

4. Infections Can Trigger Transient aPL

This became glaringly obvious during COVID-19. Multiple studies showed that nearly half of hospitalized COVID patients had positive aPL results. These were overwhelmingly transient and did NOT carry the same thrombotic risk as true APS. Other infections that commonly trigger aPL include HCV, HIV, EBV, syphilis, and Lyme disease. The lesson: always repeat at 12 weeks, and always consider the clinical context.

5. False-Positive Syphilis Testing

The VDRL and RPR tests for syphilis use cardiolipin as an antigen. Patients with anticardiolipin antibodies can therefore have a biologically false-positive syphilis test. If your patient has a positive RPR but a negative treponemal test (FTA-ABS or TP-PA), consider aPL as the explanation—especially in a patient with SLE or suspected APS.

6. Low-Titer Positives Are Usually Noise

Low-positive aCL or aβ2GPI (between the 95th and 99th percentile) are common in the general population and rarely clinically significant for thrombotic APS. The 2023 classification criteria only count moderate-to-high titers. An exception: in obstetric APS, some experts consider persistent low-titer positivity clinically relevant, particularly if other risk factors are present.

When Should NPs Order This Panel?

Test When You See

• Unprovoked venous thromboembolism, especially in patients <50
• Arterial thrombosis in a young patient (stroke, MI) without traditional risk factors
• Recurrent pregnancy losses (≥3 before 10 weeks, or ≥1 at/after 10 weeks with normal fetal morphology)
• Preeclampsia or placental insufficiency before 34 weeks
• Unexplained thrombocytopenia (especially in an SLE patient)
• Livedo racemosa (lace-like purplish skin mottling)
• An SLE patient with any thrombotic event or pregnancy complication
• Biologically false-positive syphilis test (positive RPR, negative treponemal)

Do NOT Test

• As a routine screen in asymptomatic patients
• For a single provoked DVT with clear risk factors (post-surgical, immobilization, OCP use)
• As a "just in case" add-on to an ANA panel
• In the acute setting of an infection (wait until it's resolved and repeat at 12 weeks)

The 2023 ACR/EULAR Criteria: What Changed

The updated classification system introduced a weighted scoring approach across six clinical domains (macrovascular VTE, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, and hematologic) and two laboratory domains (LA and solid-phase aCL/aβ2GPI assays). Patients need at least 3 points in both clinical AND laboratory domains to be classified as APS. The key takeaway for primary care: the bar for classification is now higher and more specific, which means fewer false-positive classifications but also a reminder that clinical diagnosis may still apply even when the scoring threshold isn't met.

Quick-Reference: The aPL Panel at a Glance

Test	Method	Key Pitfall	Affected by Anticoagulation?
Lupus Anticoagulant	Functional clotting assay (dRVVT, sensitive aPTT)	Strongest predictor, but affected by nearly all anticoagulants	Yes — heparin, warfarin, DOACs all interfere
Anticardiolipin (IgG/IgM)	ELISA immunoassay	Low titers are usually non-specific; IgG more significant than IgM	No
Anti-β2GPI (IgG/IgM)	ELISA immunoassay	Adds sensitivity; some APS patients are positive only for this	No

Bottom Line

APS is a real, serious, and treatable condition. But the lab panel is more nuanced than most providers realize. The three cardinal rules: always order all three tests together, always confirm at 12 weeks, and always interpret in clinical context. A single low-positive result on one test in an elderly patient after a provoked DVT is not the same as triple positivity in a 28-year-old with two unexplained pregnancy losses.

Know when to test, know when to wait, and know when to refer. Your hematologist and rheumatologist will thank you for sending them a patient with a properly collected, properly timed, complete panel rather than a single random aCL drawn during an acute COVID hospitalization.

Stay sharp out there.

Decoding the Hepatitis Panel: A No-Nonsense Guide for NPs Five markers, dozens of combinations, one cheat sheet you'll actually use in clinic.

 

If you've ever stared at a hepatitis B panel wondering what all those positives and negatives actually mean, you're not alone. This is one of the most commonly misinterpreted lab panels in primary care—and getting it wrong can mean missing a chronic infection, over-vaccinating a patient who's already immune, or sending someone into a panic unnecessarily.

Let's break it down.

The Big Five: Hepatitis B Markers

A standard hepatitis B panel involves five serologic markers. Each one tells a different part of the story:

• HBsAg (Surface Antigen) — The hallmark of active infection. If this is positive, the patient is infected and infectious. Present in both acute and chronic HBV.
• Anti-HBs (HBsAb) (Surface Antibody) — The protective antibody. Develops after recovery from infection OR after successful vaccination. A level >10 mIU/mL is considered protective.
• Anti-HBc total (HBcAb) (Core Antibody, Total) — A marker of any past or present HBV exposure. This is the one that sticks around for life. It does NOT develop from vaccination.
• IgM Anti-HBc (Core Antibody, IgM) — The acute infection marker. Positive during the "window period" when HBsAg has cleared but anti-HBs hasn't appeared yet. Also can flare in chronic HBV reactivation.
• HBeAg (e-Antigen) — Indicates active viral replication and high infectivity. Used more for monitoring chronic HBV than initial diagnosis.

The Interpretation Cheat Sheet

Here's where it all comes together. These are the most common clinical scenarios you'll see:

HBsAg	Anti-HBs	Anti-HBc (total)	IgM Anti-HBc	Interpretation
−	−	−	−	Never exposed, not immune. Susceptible. Vaccinate.
−	+	−	−	Immune due to vaccination. Anti-HBs is the only positive marker.
−	+	+	−	Immune due to past infection. Recovered. Core antibody distinguishes this from vaccine immunity.
+	−	+	+	Acute infection. IgM anti-HBc confirms it's new, not chronic.
+	−	+	−	Chronic infection. HBsAg present >6 months. Refer for HBV DNA, liver function, and specialist evaluation.
−	−	+	−	Isolated core antibody positive. See pitfall below—this one is tricky.

The Pitfalls: Where NPs Get Tripped Up

1. Isolated Anti-HBc Positive

This is the pattern that causes the most confusion. Anti-HBc is positive, but everything else is negative. What does it mean? It could be:

• A resolved infection where anti-HBs has waned below detectable levels (most common)
• A false positive (especially low-prevalence populations)
• The "window period" of acute infection (check IgM anti-HBc)
• Occult HBV infection (rare but real—check HBV DNA if concerned)

Clinical Pearl

Patients with isolated anti-HBc should receive one dose of HBV vaccine and then have anti-HBs rechecked in 4–8 weeks. A robust response (>100 mIU/mL) confirms prior immunity. A weak or absent response warrants completing the full vaccine series.

2. Don't Confuse Vaccine Immunity with Natural Immunity

Vaccine immunity = anti-HBs positive ONLY. Natural immunity = anti-HBs positive AND anti-HBc positive. If you see both, the patient had a prior real infection, not just a vaccine. This matters for patient counseling and medical history documentation.

3. Anti-HBs Can Wane Over Time

A patient who was successfully vaccinated years ago may show undetectable anti-HBs. This does NOT necessarily mean they've lost immunity. Immune memory (anamnestic response) often persists even when antibody levels drop. Per current CDC guidance, healthy individuals who completed the HBV series generally do not need boosters, even if anti-HBs is undetectable—unless they are in a high-risk group (healthcare workers, dialysis patients, immunocompromised).

4. HBsAg Positive ≠ Chronic Infection (Yet)

A single positive HBsAg tells you the patient is currently infected. But "chronic" requires persistence for >6 months. Always recheck at 6 months if the initial context suggests acute infection. The IgM anti-HBc helps differentiate: if it's positive, the infection is likely new.

5. Don't Forget Hepatitis C

The Hep C panel is much simpler but has its own trap:

• Anti-HCV antibody = screening test. A positive result means the patient was ever exposed. It does NOT distinguish current from past/cleared infection.
• HCV RNA (viral load) = the confirmatory test. If RNA is positive, the patient has active viremia and needs treatment. If RNA is negative, they either cleared the virus spontaneously (~25% do) or were previously treated and cured.

Pitfall

A positive anti-HCV with a negative HCV RNA does NOT mean false positive. It means the patient was truly infected and has cleared the virus. The antibody persists for life. Always order HCV RNA to confirm active infection before referring or starting treatment.

6. Hepatitis A: Quick Refresher

Not a chronic disease, but worth reviewing since it shows up on panels:

• IgM anti-HAV = acute hepatitis A infection (current or very recent)
• Total anti-HAV (IgG) = immunity from past infection OR vaccination

There is no chronic hepatitis A. A positive total anti-HAV in an asymptomatic patient simply means they're immune.

When to Order What

Ordering Guide

• Universal screening: CDC recommends all adults 18+ be screened for HBV at least once (HBsAg, anti-HBs, anti-HBc total—the "triple panel")
• Post-vaccination immunity check: Anti-HBs only (healthcare workers, dialysis patients, immunocompromised)
• Suspected acute hepatitis: Full panel including IgM anti-HBc, plus hepatitis A IgM, HCV antibody, and HCV RNA
• Monitoring chronic HBV: HBV DNA, HBeAg/anti-HBe, ALT, and periodically HBsAg quantification
• Before immunosuppression: HBsAg plus anti-HBc at minimum (reactivation risk in occult HBV)
• HCV screening: One-time anti-HCV for all adults 18+; if positive, reflex to HCV RNA

Special Considerations for Autoimmune Patients

This one is particularly important for NPs managing patients on immunosuppressive therapy:

• Rheumatoid factor (RF) can cause false-positive hepatitis serologies—RF can interfere with some immunoassays. Always correlate with clinical picture.
• HBV reactivation risk is real with rituximab, TNF inhibitors, high-dose corticosteroids, and other biologics. Screen before starting immunosuppression, even if the patient thinks they were vaccinated. Anti-HBc positive patients (even without HBsAg) can reactivate.
• HCV and cryoglobulinemia—if your autoimmune patient has an unexplained positive RF, low C4, or purpura, always check HCV. Mixed cryoglobulinemia is commonly driven by chronic HCV infection.
• SLE patients may have biologically false-positive syphilis tests (RPR/VDRL) due to antiphospholipid antibodies. This is a different pitfall, but it often comes up in the same workup.

Bottom Line

The hepatitis panel isn't hard once you understand what each marker represents. The key mistakes to avoid: confusing vaccine immunity with natural immunity, panicking over isolated anti-HBc, forgetting to confirm HCV antibody with RNA, and missing the HBV reactivation risk before immunosuppression.

Print out that interpretation table. Tape it to your desk. You'll use it more than you think.

Stay sharp out there.